Merck ROI - Return on Investment 2010-2025 | MKKGY

Merck return on investment for the quarter ending March 31, 2025 was 7.66.

  • Merck average return on investment for 2024 was 7.42, a 10.28% increase from 2023.
  • Merck average return on investment for 2023 was 8.27, a 19.4% decline from 2022.
  • Merck average return on investment for 2022 was 10.26, a 1.79% decline from 2021.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.

Merck ROI - Return on Investment 2010-2025 | MKKGY

  • Merck average return on investment for 2024 was 7.42, a 10.28% increase from 2023.
  • Merck average return on investment for 2023 was 8.27, a 19.4% decline from 2022.
  • Merck average return on investment for 2022 was 10.26, a 1.79% decline from 2021.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$81.7B
Zoetis (ZTS)$66.3B
Daiichi Sankyo, - (DSNKY)$46.4B
Takeda Pharmaceutical (TAK)$43.3B
BeOne Medicines - (ONC)$32.9B
Sandoz Group AG (SDZNY)$25.9B
Summit Therapeutics (SMMT)$19.8B
Shionogi (SGIOY)$14.3B
Neurocrine Biosciences (NBIX)$13.5B
United Therapeutics (UTHR)$12.7B
Orion OYJ (ORINY)$11.5B
IPSEN (IPSEY)$10.8B
Stevanato Group S.p.A (STVN)$7.6B
Grifols, S.A (GRFS)$7.5B
Corcept Therapeutics (CORT)$7.4B
Ionis Pharmaceuticals (IONS)$6.9B
Madrigal Pharmaceuticals (MDGL)$6.4B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.3B
Hypermarcas (HYPMY)$3.1B
Crinetics Pharmaceuticals (CRNX)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
NewAmsterdam Pharma (NAMS)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.7B